gemcitabine + carboplatin + cisplatin
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Non Small Cell Lung
Conditions
Carcinoma, Non Small Cell Lung
Trial Timeline
Sep 1, 2001 → Jul 1, 2006
NCT ID
NCT00191230About gemcitabine + carboplatin + cisplatin
gemcitabine + carboplatin + cisplatin is a phase 2 stage product being developed by Eli Lilly for Carcinoma, Non Small Cell Lung. The current trial status is completed. This product is registered under clinical trial identifier NCT00191230. Target conditions include Carcinoma, Non Small Cell Lung.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Non Small Cell Lung were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00191230 | Phase 2 | Completed |
Competing Products
20 competing products in Carcinoma, Non Small Cell Lung